Physiomics wins new contract with French pharma company

Physiomics said on Friday that it will provide specialist mathematical modelling services to Servier, which has a particular focus on immunotherapies and monoclonal antibodies for difficult to treat diseases, using its Virtual Tumour software platform to model and simulate the effect of a number of immuno-oncology combinations involving Servier drugs in development in pre-clinical and clinical settings.

The AIM-listed firm anticipates that the project will be completed over the course of the next seven to eight months.

Financial terms of the deal were not disclosed.

Chief executive Dr Jim Millen said : "We are delighted to have been selected by Servier, one of France's leading pharmaceutical companies with a truly global outlook as its partner for this modelling and simulation project focused on pre-clinical and translational modelling of a novel immuno-oncology agent in development."

As of 1030 BST, Physiomics shares were down 3.96% at 4.35p.